Molina Healthcare, Inc.
MOHMolina Healthcare, Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
The sharpest disagreement: the price moved +23.4% in a year while annual EPS moved −56.3% — the difference is re-rating, and re-rating has to be repaid with earnings.
The price is topping out (16 weeks in). Underneath, the last four quarters read deteriorating — profit −96.7% year on year, and 64% of the last 3 years' profit arrived as cash. What settles it: whether earnings grow into a price that has already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Molina Healthcare, Inc. trades at $191, losing momentum at the top and 16 weeks into that stage. That is +10.8% against its own 200-day average. It sits at 59% of a 52-week range of $132 to $233. On relative strength it is currently behind the S&P 500 on a trailing-13-week view (2 weeks and counting).
Today the stock is losing momentum at the top — week 16 of stage 3. At $191 it trades +10.8% versus its 200-day average and sits at 59% of its 52-week range ($132–$233).
Against the market, two honest reads. Cumulative: over the last 10.1 years the stock moved +281% while the S&P 500 moved +263% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (2 weeks and counting; last ahead the week of 2026-07-24) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
Molina Healthcare, Inc. trades at 62.9× P/E, against too little history to rank. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 62.9× is against too little history to rank. This is a comparison against the stock's own history — not a claim about what it is worth.
🚨 Why the multiple sits where it does: over the past year annual EPS moved −56.3% against a +23.4% price move — the price outran earnings, pushing the multiple UP its own range.
The price move, decomposed: over 3y, of the −14.2%/yr price move, ~−40.2%/yr came from earnings growth and ~+26.0 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Deteriorating Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Molina Healthcare, Inc. reads as deteriorating on its fundamental arc. Deteriorating — profit and EPS growth are shrinking (profit growth −83.9% latest against +36.3% at its 12-quarter best), ROCE slipping at 5.2%. The read is built from 12 quarters across 4 curves, on full evidence.
🚨 Why it matters: falling curves mean every cheap-looking ratio below needs a discount for direction.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +11.8% | +12.4% | — | — |
| Profit | −60.2% | −15.9% | — | — |
| EPS | −56.3% | −13.0% | — | — |
| Stock price | +23.4% | −14.2% | −6.3% | +12.5% |
4-Factor Sector Score
34.1/100 — rank 11 of 11 in Healthcare Plans · 58% evidence confidence
Molina Healthcare, Inc. scores 34.1 out of 100 against the 11 companies it is compared with in Healthcare Plans, ranking 11. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
The four contributions add to the total exactly: 11.4 + 5.8 + 9.2 + 7.7 = 34.1. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Molina Healthcare, Inc. reported $10.8 B of revenue in the Mar 26 quarter, −3.1% year on year. Over 4 years it has compounded at 13.1% a year. The last full year, FY25, came in at $45.4 B. The last four reported quarters add to $45.1 B.
FY25 revenue came in at $45.4 B (+11.8% on the year), capping 4 years at 13.1% compound. The latest quarter (Mar 26) printed $10.8 B, −3.1% year on year.
Pace check: the last four quarters averaged +8.0% growth against the decade's 13.1% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +7.7% over the last 4 quarters against +12.1%/yr over the last 8 — rolling over; TTM profit −83.9% vs −57.9%/yr — rolling over.
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Molina Healthcare, Inc.'s operating margin is 0.7% in the Mar 26 quarter, −3.2 percentage points against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 1.7% to 4.6%. The current quarter is running below every full year in that window.
The latest quarter's operating margin is 0.7%, −3.2 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 1.7%–4.6%.
🚨 Why the margin moved: operating margin went −3.2 pp year on year while gross margin went −0.8 pp — the loss came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Molina Healthcare, Inc. earned $0.0 B of net profit in the Mar 26 quarter, −96.7% year on year. Full-year FY25 profit was $0.5 B. The 4-year compound rate is −8.1%. That is 0.1% of the quarter's revenue. The same quarter a year earlier earned $0.3 B. 1 of the last 12 reported quarters were loss-making.
Mar 26 profit was $0.0 B, −96.7% year on year. On the full year, FY25 printed $0.5 B (−60.2%), and the 4-year compound rate is −8.1%.
🚨 Why profit moved: revenue contributed −3.1% and the margin −3.2 pp — the quarter was revenue-led despite a thinner margin.
Pace comparison, last four quarters: profit −87.5% vs revenue +8.0%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 64% of Molina Healthcare, Inc.'s reported profit arrived as operating cash — most of the profit is real cash. In FY25 that was $−0.5 B of operating cash against $0.5 B of profit. After $0.1 B of capital spending, $−0.6 B was left as free cash.
FY25: operating cash of $−0.5 B against reported profit of $0.5 B, leaving free cash of $−0.6 B after $0.1 B of capital spending. Across the last 3 fiscal years the conversion rate is 64% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
🚨 Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Molina Healthcare, Inc. does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $0.0 B over the last 3 years. Averaged over those years that is 0.0% of FY25 revenue a year.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $0.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
Molina Healthcare, Inc. earns a ROE of 12% in FY25. Return on invested capital clears the cost of that capital by −3.5 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 1.0% net margin on 2.92× asset turns.
FY25 ROE is 12%.
🚨 Why the return is what it is — the wiring (FY25): 1.0% net margin × 2.92× asset turns × 3.82× balance-sheet leverage ≈ 11.2% on equity. Margin does its share; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 3.7% − 7.2% = a −3.5 pp spread. The 7.2% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
Dividend
Molina Healthcare, Inc. pays no dividend. Across the last 12 reported quarters it has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings rather than distribute them, which makes the cash-flow and reinvestment sections the place that cash shows up.
Molina Healthcare, Inc. does not currently pay a dividend. Across the last 12 reported quarters the company has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings instead of distributing them.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Molina Healthcare, Inc. carries total debt of $4.0 B against shareholder equity of $4.2 B as of Jun 26, a debt-to-equity of 0.95. On the annual view that ratio went from 0.91 in FY21 to 0.97 in FY25. Read the returns elsewhere on this page with that leverage in mind.
Jun 26: total debt of $4.0 B against shareholder equity of $4.2 B — a debt-to-equity of 0.95. On the annual view, debt-to-equity went from 0.91 (FY21) to 0.97 (FY25). Read the returns on this page with that leverage in mind.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
6.9% of Molina Healthcare, Inc.'s tradable float is currently sold short — some money is positioned against it. At typical trading volumes those positions would take about 3.1 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 6.9% of the float is sold short, and at typical trading volumes it would take about 3.1 days to buy those positions back. Some money is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Molina Healthcare, Inc.: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Progyny, Inc.PGNY | 70.9/100Favorable setup81% evidence | LEADER | 24.9/35 Revenue 6.6% · PAT 28.9% · OPM change 3.3 pp 83% evidence | 14.6/25 ROCE 7.4% · OPM 10.8% 76% evidence | 15.5/20 P/E 22.1× · PEG 0.63 65% evidence | 15.9/20 RS sector 6.6% · RS bench 21.3% · 1Y 37.8%12 of 12 weeks ahead 100% evidence |
| Exact sum: 24.9 + 14.6 + 15.5 + 15.9 = 70.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2Oscar Health, Inc.OSCR | 68.6/100Favorable setup71% evidence | LEADER | 21.5/35 Revenue 32% · PAT -130.4% · OPM change 5.4 pp 83% evidence | 18.3/25 ROCE 36.6% · OPM 15.2% 76% evidence | 8.8/20 P/E 46.8× · PEG — 15% evidence | 20.0/20 RS sector 29.2% · RS bench 44.7% · 1Y 96.5%12 of 12 weeks ahead 100% evidence |
| Exact sum: 21.5 + 18.3 + 8.8 + 20 = 68.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Clover Health Investments, Corp.CLOV | 63.1/100Mixed-positive evidence61% evidence | LEADER | 25.0/35 Revenue 48.9% · PAT — · OPM change 3.9 pp 62% evidence | 9.7/25 ROCE 7.5% · OPM 3.6% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 18.4/20 RS sector 16.3% · RS bench 30% · 1Y 95.9%12 of 12 weeks ahead 100% evidence |
| Exact sum: 25 + 9.7 + 10 + 18.4 = 63.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Centene CorporationCNC | 53.9/100Thin evidence · provisional58% evidence | LEADER | 19.2/35 Revenue — · PAT — · OPM change 0.4 pp 45% evidence | 8.1/25 ROCE 2.6% · OPM 3.7% 76% evidence | 11.2/20 P/E 13.4× · PEG — 15% evidence | 15.4/20 RS sector 15.6% · RS bench 30.3% · 1Y 150.4%12 of 12 weeks ahead 100% evidence |
| Exact sum: 19.2 + 8.1 + 11.2 + 15.4 = 53.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 5Humana Inc.HUM | 46.6/100Thin evidence · provisional58% evidence | LEADER | 13.8/35 Revenue — · PAT — · OPM change -1.9 pp 45% evidence | 7.5/25 ROCE 2.5% · OPM 4.4% 76% evidence | 9.5/20 P/E 37.6× · PEG — 15% evidence | 15.8/20 RS sector 7.1% · RS bench 20.6% · 1Y 35.8%12 of 12 weeks ahead 100% evidence |
| Exact sum: 13.8 + 7.5 + 9.5 + 15.8 = 46.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 6UnitedHealth Group IncorporatedUNH | 46.3/100Mixed-negative evidence85% evidence | FADING | 13.6/35 Revenue 6.5% · PAT -32.5% · OPM change 2.5 pp 95% evidence | 10.9/25 ROCE 2.6% · OPM 7.1% 76% evidence | 15.2/20 P/E 26.7× · PEG 0.73 65% evidence | 6.6/20 RS sector -6.4% · RS bench 6.7% · 1Y 62.4%11 of 12 weeks ahead 100% evidence |
| Exact sum: 13.6 + 10.9 + 15.2 + 6.6 = 46.3 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 7CVS Health CorporationCVS | 44.8/100Mixed-negative evidence71% evidence | LEADER | 13.6/35 Revenue 7.6% · PAT -44.6% · OPM change 1.1 pp 83% evidence | 11.4/25 ROCE 2.8% · OPM 4.7% 76% evidence | 9.8/20 P/E 31.6× · PEG — 15% evidence | 10.0/20 RS sector -1.1% · RS bench 12.9% · 1Y 59.3%11 of 12 weeks ahead 100% evidence |
| Exact sum: 13.6 + 11.4 + 9.8 + 10 = 44.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8The Cigna GroupCI | 39.4/100Thin evidence · provisional58% evidence | ASLEEP | 16.2/35 Revenue — · PAT — · OPM change 0.4 pp 45% evidence | 10.0/25 ROCE 2.7% · OPM 3.4% 76% evidence | 11.5/20 P/E 11.4× · PEG — 15% evidence | 1.7/20 RS sector -24.7% · RS bench -13% · 1Y -0.3%0 of 12 weeks ahead 100% evidence |
| Exact sum: 16.2 + 10 + 11.5 + 1.7 = 39.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 9Alignment Healthcare, Inc.ALHC | 37.2/100Thin evidence · provisional58% evidence | ASLEEP | 18.5/35 Revenue — · PAT — · OPM change 1.9 pp 45% evidence | 10.2/25 ROCE 7.9% · OPM 1.3% 76% evidence | 8.5/20 P/E 125.3× · PEG — 15% evidence | 0.0/20 RS sector -43.3% · RS bench -34.6% · 1Y -6.8%3 of 12 weeks ahead 100% evidence |
| Exact sum: 18.5 + 10.2 + 8.5 + 0 = 37.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 10Elevance Health, Inc.ELV | 35.8/100Thin evidence · provisional58% evidence | FADING | 13.6/35 Revenue — · PAT — · OPM change -2.2 pp 45% evidence | 8.7/25 ROCE 2.1% · OPM 4% 76% evidence | 10.8/20 P/E 17.2× · PEG — 15% evidence | 2.7/20 RS sector -14.5% · RS bench -2.1% · 1Y 28.6%10 of 12 weeks ahead 100% evidence |
| Exact sum: 13.6 + 8.7 + 10.8 + 2.7 = 35.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 11Molina Healthcare, Inc.this pageMOH | 34.1/100Thin evidence · provisional58% evidence | FADING | 11.4/35 Revenue — · PAT — · OPM change -3.1 pp 45% evidence | 5.8/25 ROCE 1.7% · OPM 0.8% 76% evidence | 9.2/20 P/E 39.4× · PEG — 15% evidence | 7.7/20 RS sector -13.3% · RS bench -1.2% · 1Y 22%9 of 12 weeks ahead 100% evidence |
| Exact sum: 11.4 + 5.8 + 9.2 + 7.7 = 34.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Molina Healthcare, Inc.'s stock price today?
Molina Healthcare, Inc. trades at $191, +23.4% over the past year. The company is valued at $10.0 B. The stock sits at 59% of its 52-week range of $132–$233, +10.8% versus its 200-day average. On the tape, the price is topping out, 16 weeks in. — as of 5 August 2026.
What were Molina Healthcare, Inc.'s latest quarterly results?
Molina Healthcare, Inc. reported revenue of $10.8 B and net profit of $0.0 B for the Mar 26 quarter. Revenue fell 3.1% and profit fell 96.7% year on year. Earnings per share were $0.27. The operating margin was 0.7%, 3.2 pp lower than a year earlier. — as of 5 August 2026.
What is Molina Healthcare, Inc.'s revenue?
Molina Healthcare, Inc. reported revenue of $10.8 B in the Mar 26 quarter, −3.1% year on year. For the full FY25 fiscal year, revenue was $45.4 B (+11.8%). Over the last 4 years revenue compounded at 13.1% a year. — as of 5 August 2026.
What is Molina Healthcare, Inc.'s profit?
Molina Healthcare, Inc. earned $0.0 B of net profit in the Mar 26 quarter, −96.7% year on year. Full-year FY25 profit was $0.5 B. The operating margin ran 0.7% in the latest quarter. — as of 5 August 2026.
What is Molina Healthcare, Inc.'s market cap?
Molina Healthcare, Inc.'s market capitalisation is $10.0 B at a stock price of $191. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 5 August 2026.
Does Molina Healthcare, Inc. pay a dividend?
No — Molina Healthcare, Inc. has declared no dividend per share in any of its last 12 reported quarters, so there is no payout history and no yield to quote. That is a reading of the filed statements, not an estimate. — as of 5 August 2026.
Is Molina Healthcare, Inc. growing?
Not right now — Molina Healthcare, Inc.'s latest numbers are shrinking: latest-quarter revenue −3.1% year on year, profit −96.7%, and the margin −3.2 pp at 0.7%. The 4-year compound rates are 13.1% (revenue) and −8.1% (profit). The earnings engine currently reads: deteriorating — as of 5 August 2026.
How is Molina Healthcare, Inc. performing?
Molina Healthcare, Inc. is topping out, 16 weeks in. Its latest quarter's revenue fell 3.1% and profit fell 96.7% year on year. Against the S&P 500 it has been behind on a trailing-13-week view for 2 weeks. This describes what the data did, not a rating. — as of 5 August 2026.
What stage is Molina Healthcare, Inc. in?
Deteriorating — profit and EPS growth are shrinking (profit growth −83.9% latest against +36.3% at its 12-quarter best), ROCE slipping at 5.2%. The read comes from the last 12 quarters of growth (revenue growth +7.7% latest, profit growth −83.9% latest, eps growth −83.7% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 5 August 2026.
Is Molina Healthcare, Inc. in an uptrend?
It is stalling — the price is topping out (week 16 of stage 3), trading +10.8% versus its 200-day average and at 59% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 5 August 2026.
Is Molina Healthcare, Inc. beating the market?
Not lately — on a trailing-13-week view Molina Healthcare, Inc. is currently behind the S&P 500 (2 weeks and counting; last ahead the week of 2026-07-24), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.1 years the stock moved +281% against the S&P 500's +263% — ahead of the index over the full window. — as of 5 August 2026.
Will Molina Healthcare, Inc.'s stock price go up?
This page publishes no price forecast for Molina Healthcare, Inc. What it measures instead: the stock price is $191, the price is topping out 16 weeks in. Direction is not something this site claims to know. — as of 5 August 2026.
Is the market betting against Molina Healthcare, Inc.?
Somewhat — short interest is 6.9% of Molina Healthcare, Inc.'s tradable float, about 3.1 days to cover at typical volumes. A moderate reading: some money is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 5 August 2026.
Does Molina Healthcare, Inc. have too much debt?
It is moderate — Molina Healthcare, Inc.'s debt-to-equity is 0.95. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. Read the returns on this page with that leverage in mind — as of 5 August 2026.
What is Molina Healthcare, Inc.'s capex?
Molina Healthcare, Inc. spent $0.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $0.1 B. — as of 5 August 2026.
What is Molina Healthcare, Inc.'s cash flow?
Molina Healthcare, Inc. generated $−0.5 B of operating cash flow in FY25 and $−0.6 B of free cash flow after $0.1 B of capital spending. Reported profit that year was $0.5 B, so operating cash ran behind profit. — as of 5 August 2026.
Is Molina Healthcare, Inc.'s profit real cash?
Mostly — over the last 3 fiscal years, 64% of Molina Healthcare, Inc.'s reported profit arrived as operating cash. In FY25, operating cash was $−0.5 B against reported profit of $0.5 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 5 August 2026.
Where is Molina Healthcare, Inc. in its business cycle?
Molina Healthcare, Inc.'s FY25 operating margin was 1.7%, against a 5-year band of 1.7%–4.6%: the low end of its own band, which is where recoveries start when they come. The latest quarter ran 0.7%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 5 August 2026.
What could break the Molina Healthcare, Inc. story?
The sharpest disagreement: the price moved +23.4% in a year while annual EPS moved −56.3% — the difference is re-rating, and re-rating has to be repaid with earnings. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 5 August 2026.
Is Molina Healthcare, Inc. a stock worth studying right now?
This is not investment advice. The machine read: Molina Healthcare, Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: whether earnings grow into a price that has already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 5 August 2026.